June 03, 2016 + Jessica Di Palo
5 Min read
Providing the best possible rehabilitation treatment to intensive-care patients, already 24 hours after hospital admission, directly into the patient bed: ReActive Robotics aims to make intelligent robotics the standard-of care in a field that has been dominated by manual therapy. A consortium of four investors, led by MTIP MedTech Innovation Partners AG and complemented by the High-Tech Gruenderfonds, Bayern Kapital and TQ-Group, provides a seven-digit series-A to enable the development and clinical validation of several prototype until 2017.
Gilching, June 2nd, 2016 – „The demographic change and a continuous increase of healthcare cost require intelligent automation solutions in therapy and care of heavily affected patients”, explains Dr. Alexander Koenig, founder and CEO of ReActive Robotics. “This fresh capital enables us to develop a robotics therapy prototype and clinically validate our early-mobilization concept in the intensive care unit”.
ReActive Robotics develops adaptive and intelligent therapy robotics which automate early-mobilization in the intensive care unit. Using robotic modules that can be attached and detached on and from the patient bed, patients can be mobilized directly in their hospital bed. As compared to existing solutions, this approach supersedes the time-intensive and dangerous transfer of the patient onto a separate therapy device. The market size is estimated to exceed € 2 bn. The device is scheduled to become available in Europe the beginning of 2018.
Clinical studies demonstrate that intensive care unit patients that receive early mobilization can leave the hospital on average three days earlier which can lead to large cost savings. The improved therapy results can, however, only be achieved if the patient is mobilized several times per day. Manually providing such early-mobilization is expensive, as up to three therapists and nurses are required to move the patient. In comparison, the solution developed by ReActive Robotics can be operated by one care-taker. The therapist is alleviated from the heavy manual work by the robotics device and can focus on the patient. The therapy thereby not only becomes more cost effective but also more personal. “ReActive Robotics’ innovation represents a shining example of reducing therapy costs while improving patient benefits, and delivers a valuable contribution to the future sustainability of our healthcare system”, says Dr. Christoph Kausch, CEO of lead investor MTIP with regard to the investment.
About ReActive Robotics
ReActive Robotics was founded in Munich, Germany, in April 2015 with the vision to enable intensive care personnel to deliver the best possible rehabilitation therapy to their patients. As part of the Business Incubation Center of the European Space Agency ESA-BIC Bavaria, the team around the founder, Dr. Alexander Koenig, could win TQ-Group, one of the leading Technology companies with broad robotics know-how, as its partner in July 2015. ReActive Robotics was supported by the UnternehmerTUM and BayStartUP and already succeeded twice in the Munich Businessplan Competition 2016.
ReActive Robotics GmbH
Dr. Alexander König
Friedrichshafener Str. 1
82205 Gilching b. München
Tel.: +49 8105 772 7762
About High-Tech Gruenderfonds
High-Tech Gruenderfonds invests in young, high potential high-tech start-ups. The seed financing provided is designed to enable start-ups to take an idea through prototyping and to market launch. Typically, High-Tech Gruenderfonds invests € 600,000 in the seed stage, with the potential for up to a total of € 2 mn per portfolio company in follow-on financing. Investors in this public/private partnership include the Federal Ministry of Economics and Energy, the KfW Banking Group, as well as strategic corporate investors including ALTANA, BASF, Bayer, B. Braun, Robert Bosch, CEWE, Daimler, Deutsche Post DHL, Deutsche Telekom, Evonik, Lanxess, media + more venture Beteiligungs GmbH & Co. KG, METRO, Qiagen, RWE Innogy, SAP, Tengelmann and Carl Zeiss. High-Tech Gruenderfonds has about € 576 mn under management in two funds (€ 272 mn HTGF I, € 304 mn HTGF II).
High-Tech Gründerfonds Management GmbH
Dr. Sebastian Schöfer
53113 BonnTel.: +49 228 823001-00
Fax: +49 228 823000-50
About Bayern Kapital
Bayern Kapital GmbH, based in Landshut, was founded on the initiative of the Bavarian government in 1995. It is a wholly-owned subsidiary of the Bavarian LfA Förderbank . As the venture capital organisation of the Land of Bavaria, Bayern Kapital provides equity capital financing for the founders of young innovative technology companies in Bavaria.
Presently Bayern Kapital manages eleven investment funds with a total volume of around
€ 340 mn. So far, it has invested almost € 220 mn in 240 innovative companies in the fields of technology in various sectors including life science, software & IT, medical technology, materials and new materials, nanotechnology and environmental technology.
In this way, almost 5,000 long-term jobs in sustainable companies have been created in Bavaria.
Bayern Kapital GmbH
Ländgasse 135 a
Tel.: +49 871 92325-0
Tel.: +49 89 2000 30-30
As an electronics service provider (E²MS supplier and CEM) TQ offers the complete range of services from development, through production and service right up to product life cycle management. The services cover assemblies, equipment and systems including hardware, software and mechanics. Customers can obtain all services from TQ on a modular basis as individual services and also as a complete package according to their individual requirements. Standard products such as finished microcontroller modules (minimodules), drive and automation solutions complete the range of services.
Through the combination of electronics services and finished system components, TQ offers customer-specific products as ODM products and thereby addresses customers who would like to receive finished products and at the same time benefit from the advantages of a customer-specific solution. ODM products are provided on time and economically using a comprehensive solution kit. The kit includes finished electronic, mechanical and software components including certification and licenses.
The TQ Group employs approx. 1,400 colleagues at their 13 sites (11 x Germany, 1 x Switzerland, 1 x China).
Phone: +49 8153 9308-245
About ESA-BIC Bavaria
The ESA Business Incubation Centre in Bavaria, Germany, was founded in 2009 and is managed by Anwendungszentrum GmbH Oberpfaffenhofen (AZO). Together with its partners the centre offers business start-up support as well as technical expertise in many space related areas, among others in satellite navigation, data systems, robotics and software systems.
ESA BIC Bavaria has business incubation offices at four locations in the region: the headquarters in Oberpfaffenhofen, and branch offices in Nürnberg, Berchtesgadener Land and Ottobrunn.
Anwendungszentrum GmbH Oberpfaffenhofen
Tel.: +49 8105 77 2 77-17
Dealroom Report: Tooling the Physicians of the Future
European startups addressing clinical capacity bottlenecks
MTIP Office Featured in Swiss Office Blog
MTIP Office Featured in Swiss Office Blog
Diversity, Equity, and Inclusion: The 3 Key Drivers for Success
We have talked with Caroline Noublanche, CEO of our portfolio company Apricity, about her company’s DEI efforts.
Growth Capital Decisions – An Interview with our Co-Founder & Managing Partner Dr. Christoph Kausch
Growth Capital Decisions
Rahel Hafner Receives Certificate in ESG Investing by CFA Institute
Rahel Hafner Receives Certificate in ESG Investing
What Makes a Great Founder/Investor Relationship?
Interview with the CEO and Co-Founder Kai Eberhardt of our portfolio company Oviva
MTIP’s HealthCare Clinic 2022
This year's HealthCare Clinic was held under the motto: "Surfing the Healthtech Waves of Change".
Christoph Kausch selected by Real Deals as most influential for 2022
Christoph Kausch named by Real Deals most influential for 2022
MTIP leads €17 million financing round in virtual fertility clinic Apricity
New MTIP investment
MTIP leads the €20 million growth financing round in LynxCare
Largest capital round ever in digital health in Belgium
Pioneering the use of machine learning algorithms to turbo-charge drug development
Intelligencia revolutionizes drug development
The psychology of decision making
What makes a good investor?
Revolutionizing medical triage with artificial intelligence
Mediktor's solution for medical triage
MTIP Closes Second Healthtech Growth Fund Above Target With $250M of Commitments
MTIP Fund II is closed!
Cynerio Now! – A new IoT cybersecurity solution for small hospitals and clinics
Cynerio's new product Cynerio Now!
MTIP invests in Mediktor
New investment in Mediktor
SFDR Art. 8 or Art. 9? What’s the difference?
SFDR: getting the terminology right
MTIP participates in Oviva’s new $80m Series C funding
Oviva raises $80 million financing round
MTIP invests in Intelligencia to reduce the risk of clinical research through artificial intelligence
MTIP's new investment in Intelligencia
Private Equity 101: Part one – Glossary
Are you new to the healthtech space?
Leading brands revolutionize care journeys with Lumeon
How Lumeon orchestrates care journey
Trialbee – our hero in patient matching and recruiting for clinical trials
Trialbee - patient matching and recruiting
Digital healthcare: patient-first?
Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital
SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?
New SFDR obligations
MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation
First Closing of Fund II